Research themes under consideration for the next round of Innovative Health Initiative (IHI) funding include Topic 4: Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases.
Medical affairs is an increasingly complex discipline. It is vital that the team is highly trained and able to adapt to an evolving environment, liaising effectively with stakeholders to communicate value and bring new treatments to the market. Read on to discover some of the challenges and trends affecting the sector.
A fund of over £113 million has been announced today (28 November 2022) to develop innovative medicines and diagnostics for cancer, obesity, mental health and addiction in the UK population.
A report commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has led the organisation to warn that the options being discussed by policymakers around the EU Pharma Strategy fall short.
Among the measures unveiled in the UK government’s Autumn Statement, published on 17 November 2022, Chancellor of the Exchequer Jeremy Hunt said that there will be regulatory reform to encourage economic growth in key industries, including the life sciences.
Pharmacovigilance (PV) – the proactive maintenance of drug safety through collection, detection, assessment, monitoring and prevention of adverse effects – has been evolving since the first concerns were raised over the negative effects of chloroform anaesthetic in the 1800s. Today, it is just as important that pharma, start-ups and regulators keep up to date with the latest trends to ensure that drugs are safe and monitoring practices remain fit for purpose.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced a 12-month extension to its substantial reform of the Medical Device Regulations, which will now come into force by July 2024.
Scientists at MirZyme Therapeutics believe they have developed a drug that, when given to women from 20 weeks of pregnancy, could stop them developing the condition.
Wellcome has awarded £1.8m to the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) so that they can investigate and produce guidance on regulation of digital mental health tools.
The Biotechnology Innovation Organisation (BIO), Developing Countries Vaccine Manufacturers’ Network (DCVMN) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) met at the ‘Global Equity & Timely Access: COVID-19 and Beyond’ meeting in India in October and announced their support for the Berlin Declaration ‘biopharmaceutical industry vision for equitable access in pandemics’.
